Which has higher valuation & earnings, ADMA or ACET?

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 4.51 $146.93M $0.70 14.19 Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is ADMA or ACET more profitable?

ADMA Biologics has a net margin of 32.98% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to ADMA or ACET?

In the previous week, ADMA Biologics had 47 more articles in the media than Adicet Bio. MarketBeat recorded 51 mentions for ADMA Biologics and 4 mentions for Adicet Bio. ADMA Biologics' average media sentiment score of 0.05 beat Adicet Bio's score of -0.58 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 5 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Adicet Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has stronger valuation and earnings, RCKT or ACET?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A Adicet Bio N/A N/A -$116.80M -$11.45 N/A

Is RCKT or ACET more profitable?

Rocket Pharmaceuticals' return on equity of -69.61% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -69.61% -58.63% Adicet Bio N/A -74.90% -60.87%

Does the media refer more to RCKT or ACET?

In the previous week, Adicet Bio had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for Adicet Bio and 3 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.34 beat Adicet Bio's score of -0.58 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adicet Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable valuation & earnings, ACET or AGEN?

Agenus has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adicet Bio N/A N/A -$116.80M -$11.45 N/A Agenus $123.87M 2.48 $120K $2.58 2.66

Is ACET or AGEN more profitable?

Agenus has a net margin of 69.33% compared to Adicet Bio's net margin of 0.00%. Agenus' return on equity of -45.12% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Agenus 69.33% -45.12% 54.85%

Does the media prefer ACET or AGEN?

In the previous week, Agenus had 1 more articles in the media than Adicet Bio. MarketBeat recorded 5 mentions for Agenus and 4 mentions for Adicet Bio. Adicet Bio's average media sentiment score of -0.58 beat Agenus' score of -0.74 indicating that Adicet Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adicet Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Agenus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Which has better valuation & earnings, ACET or LXEO?

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adicet Bio N/A N/A -$116.80M -$11.45 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A

Is ACET or LXEO more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Lexeo Therapeutics N/A -47.48% -41.72%

Does the media favor ACET or LXEO?

In the previous week, Adicet Bio had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Adicet Bio and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Adicet Bio's score of -0.58 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adicet Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACET or LYEL?

In the previous week, Lyell Immunopharma had 3 more articles in the media than Adicet Bio. MarketBeat recorded 7 mentions for Lyell Immunopharma and 4 mentions for Adicet Bio. Lyell Immunopharma's average media sentiment score of 0.39 beat Adicet Bio's score of -0.58 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adicet Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Adicet Bio (ACET) Competitors

$8.18 +0.21 (+2.57%)

As of 11:16 AM Eastern

Compare

ACET vs. ADMA, RCKT, AGEN, LXEO, and LYEL

Should you buy Adicet Bio stock or one of its competitors? MarketBeat compares Adicet Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adicet Bio include ADMA Biologics (ADMA), Rocket Pharmaceuticals (RCKT), Agenus (AGEN), Lexeo Therapeutics (LXEO), and Lyell Immunopharma (LYEL). These companies are all part of the "biotechnology" industry.

How does Adicet Bio compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Adicet Bio (NASDAQ:ACET) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

ADMA Biologics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Adicet Bio	N/A	-74.90%	-60.87%

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 87.89%. Adicet Bio has a consensus price target of $46.80, indicating a potential upside of 471.78%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts clearly believe Adicet Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.51	$146.93M	$0.70	14.19
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

In the previous week, ADMA Biologics had 47 more articles in the media than Adicet Bio. MarketBeat recorded 51 mentions for ADMA Biologics and 4 mentions for Adicet Bio. ADMA Biologics' average media sentiment score of 0.05 beat Adicet Bio's score of -0.58 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	5 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adicet Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

ADMA Biologics beats Adicet Bio on 10 of the 16 factors compared between the two stocks.

How does Adicet Bio compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 3.4% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Rocket Pharmaceuticals presently has a consensus price target of $8.71, suggesting a potential upside of 138.42%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 471.78%. Given Adicet Bio's stronger consensus rating and higher probable upside, analysts clearly believe Adicet Bio is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Rocket Pharmaceuticals' return on equity of -69.61% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Adicet Bio	N/A	-74.90%	-60.87%

In the previous week, Adicet Bio had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for Adicet Bio and 3 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.34 beat Adicet Bio's score of -0.58 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adicet Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Rocket Pharmaceuticals has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Summary

Adicet Bio beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Adicet Bio compare to Agenus?

Adicet Bio (NASDAQ:ACET) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Adicet Bio has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Agenus has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Agenus has a net margin of 69.33% compared to Adicet Bio's net margin of 0.00%. Agenus' return on equity of -45.12% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Agenus	69.33%	-45.12%	54.85%

In the previous week, Agenus had 1 more articles in the media than Adicet Bio. MarketBeat recorded 5 mentions for Agenus and 4 mentions for Adicet Bio. Adicet Bio's average media sentiment score of -0.58 beat Agenus' score of -0.74 indicating that Adicet Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Agenus has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Agenus	$123.87M	2.48	$120K	$2.58	2.66

Adicet Bio currently has a consensus price target of $46.80, suggesting a potential upside of 471.78%. Agenus has a consensus price target of $22.00, suggesting a potential upside of 220.47%. Given Adicet Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Adicet Bio is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 3.4% of Adicet Bio shares are held by company insiders. Comparatively, 6.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Agenus beats Adicet Bio on 9 of the 16 factors compared between the two stocks.

How does Adicet Bio compare to Lexeo Therapeutics?

Adicet Bio (NASDAQ:ACET) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Lexeo Therapeutics' return on equity of -47.48% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

In the previous week, Adicet Bio had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Adicet Bio and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Adicet Bio's score of -0.58 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Adicet Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Adicet Bio presently has a consensus target price of $46.80, indicating a potential upside of 471.78%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 301.16%. Given Adicet Bio's higher probable upside, analysts plainly believe Adicet Bio is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 3.4% of Adicet Bio shares are owned by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lexeo Therapeutics beats Adicet Bio on 8 of the 14 factors compared between the two stocks.

How does Adicet Bio compare to Lyell Immunopharma?

Adicet Bio (NASDAQ:ACET) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Lyell Immunopharma had 3 more articles in the media than Adicet Bio. MarketBeat recorded 7 mentions for Lyell Immunopharma and 4 mentions for Adicet Bio. Lyell Immunopharma's average media sentiment score of 0.39 beat Adicet Bio's score of -0.58 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Adicet Bio presently has a consensus target price of $46.80, suggesting a potential upside of 471.78%. Lyell Immunopharma has a consensus target price of $42.00, suggesting a potential upside of 187.89%. Given Adicet Bio's higher possible upside, analysts clearly believe Adicet Bio is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Adicet Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Adicet Bio has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Adicet Bio's return on equity of -74.90% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Lyell Immunopharma	-920,285.25%	-87.60%	-67.85%

Adicet Bio has higher earnings, but lower revenue than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Lyell Immunopharma	$40K	8,935.76	-$274.45M	-$12.83	N/A

Summary

Adicet Bio beats Lyell Immunopharma on 9 of the 15 factors compared between the two stocks.

Get Adicet Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACET vs. The Competition

Export

Metric	Adicet Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$75.76M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.71	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.49	17.97	11.40	6.45
Net Income	-$116.80M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-11.42%	5.58%	3.66%	3.77%
1 Month Performance	-7.30%	-1.60%	-0.49%	-0.40%
1 Year Performance	-17.62%	61.32%	77.51%	23.55%

Adicet Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACET Adicet Bio	3.4658 of 5 stars	$8.19 +2.6%	$46.80 +471.8%	-19.7%	$75.76M	N/A	N/A	90	Earnings Report
ADMA ADMA Biologics	4.3336 of 5 stars	$8.74 +3.3%	$18.67 +113.6%	-40.1%	$1.96B	$510.17M	12.85	530	Earnings Report Gap Up
RCKT Rocket Pharmaceuticals	2.569 of 5 stars	$3.41 +9.6%	$8.71 +155.6%	+26.2%	$339.59M	N/A	N/A	240	News Coverage Analyst Downgrade
AGEN Agenus	3.1881 of 5 stars	$7.82 +4.3%	$22.00 +181.3%	+45.0%	$335.64M	$123.87M	4.92	440	Analyst Upgrade Gap Up
LXEO Lexeo Therapeutics	2.013 of 5 stars	$4.20 +1.7%	$18.75 +346.4%	+6.2%	$324.29M	N/A	N/A	58	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACET) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adicet Bio (ACET) Competitors

ACET vs. ADMA, RCKT, AGEN, LXEO, and LYEL

How does Adicet Bio compare to ADMA Biologics?

Summary

How does Adicet Bio compare to Rocket Pharmaceuticals?

Summary

How does Adicet Bio compare to Agenus?

Summary

How does Adicet Bio compare to Lexeo Therapeutics?

Summary

How does Adicet Bio compare to Lyell Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET vs. The Competition

Adicet Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adicet Bio (ACET) Competitors

ACET vs. ADMA, RCKT, AGEN, LXEO, and LYEL

How does Adicet Bio compare to ADMA Biologics?

Which has more risk & volatility, ADMA or ACET?

Is ADMA or ACET more profitable?

Do institutionals & insiders believe in ADMA or ACET?

Do analysts rate ADMA or ACET?

Which has higher valuation & earnings, ADMA or ACET?

Does the media refer more to ADMA or ACET?

Summary

How does Adicet Bio compare to Rocket Pharmaceuticals?

Do institutionals & insiders hold more shares of RCKT or ACET?

Which has stronger valuation and earnings, RCKT or ACET?

Do analysts recommend RCKT or ACET?

Is RCKT or ACET more profitable?

Does the media refer more to RCKT or ACET?

Which has more risk and volatility, RCKT or ACET?

Summary

How does Adicet Bio compare to Agenus?

Which has more risk and volatility, ACET or AGEN?

Is ACET or AGEN more profitable?

Does the media prefer ACET or AGEN?

Which has preferable valuation & earnings, ACET or AGEN?

Do analysts rate ACET or AGEN?

Do institutionals & insiders hold more shares of ACET or AGEN?

Summary

How does Adicet Bio compare to Lexeo Therapeutics?

Is ACET or LXEO more profitable?

Does the media favor ACET or LXEO?

Which has more risk & volatility, ACET or LXEO?

Do analysts recommend ACET or LXEO?

Which has better valuation & earnings, ACET or LXEO?

Do institutionals and insiders believe in ACET or LXEO?

Summary

How does Adicet Bio compare to Lyell Immunopharma?

Do insiders and institutionals have more ownership in ACET or LYEL?

Does the media favor ACET or LYEL?

Do analysts rate ACET or LYEL?

Which has more risk and volatility, ACET or LYEL?

Is ACET or LYEL more profitable?

Which has higher valuation and earnings, ACET or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET vs. The Competition

Adicet Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools